Total Renal Care Of North Carolina Llc is a medicare approved dialysis facility center in Jacksonville, North Carolina and it has 31 dialysis stations. It is located in Onslow county at 14 Office Park Drive, Jacksonville, NC, 28546. You can reach out to the office of Total Renal Care Of North Carolina Llc at (910) 353-6888. This dialysis clinic is managed and/or owned by Davita. Total Renal Care Of North Carolina Llc has the following ownership type - Profit. It was first certified by medicare in March, 1988. The medicare id for this facility is 342532 and it accepts patients under medicare ESRD program.
Name | Total Renal Care Of North Carolina Llc |
---|---|
Location | 14 Office Park Drive, Jacksonville, North Carolina |
No. of Dialysis Stations | 31 |
Medicare ID | 342532 |
Managed By | Davita |
Ownership Type | Profit |
Late Shifts | No |
14 Office Park Drive, Jacksonville, North Carolina, 28546 | |
(910) 353-6888 | |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
NPI Number | 1346209970 |
Organization Name | Southeastern Dialysis Center Jacksonville |
Doing Business As | Total Renal Care Of North Carolina Llc |
Address | 14 Office Park Dr Jacksonville, North Carolina, 28546 |
Phone Number | (910) 353-6888 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that nephrologists always communicated and cared for them. | 69% | 67% |
Patients who reported that nephrologists usually communicated and cared for them. | 10% | 15% |
Patients who reported that nephrologists sometimes or never communicated and cared for them. | 21% | 18% |
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 60% | 60% |
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 26% |
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 16% | 14% |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 60% | 62% |
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 20% | 20% |
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 20% | 18% |
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 51% | 62% |
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 38% | 26% |
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 11% | 12% |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Experience Measure | Provider | National Avg. |
---|---|---|
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 83% | 80% |
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 17% | 20% |
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 63% | 68% |
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 25% | 20% |
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 12% | 12% |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Dialysis patients with Hemoglobin data | 72 |
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 21 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 114 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 962 |
Percentage of adult patients getting regular hemodialysis at the center | 93 |
Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Total Renal Care Of North Carolina Llc with elevated calcium levels.
Patients with hypercalcemia | 124 |
Hypercalcemia patient months | 1074 |
Patients with Serumphosphor | 131 |
Patients with Serumphosphor less than 3.5 mg/dL | 10 |
Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 25 |
Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
Patients with Serumphosphor from 5.6 to 7 mg/dL | 18 |
Patients with Serumphosphor greater than 7 mg/dL | 16 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
Patients included in arterial venous fistula and catheter summaries | 142 |
Patient months included in arterial venous fistula and catheter summaries | 925 |
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 75 |
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 12 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 100 |
Hospitalization Rate in facility | 162.9 (As Expected) |
Hospitalization Rate: Upper Confidence Limit | 277.5 |
Hospitalization Rate: Lower Confidence Limit | 103.6 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Total Renal Care Of North Carolina Llc were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
Readmission Rate in facility | 23.2 (As Expected) |
Readmission Rate: Upper Confidence Limit | 31.3 |
Readmission Rate: Lower Confidence Limit | 16.2 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Total Renal Care Of North Carolina Llc get infections in their blood each year compared to the number of infections expected for the center based on the national average.
Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
Infection Rate in facility | .78 (As Expected) |
SIR: Upper Confidence Limit | 1.73 |
SIR: Lower Confidence Limit | .29 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Total Renal Care Of North Carolina Llc's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 80 |
Transfusion Rate in facility | 41.7 (As Expected) |
Transfusion Rate: Upper Confidence Limit | 92 |
Transfusion Rate: Lower Confidence Limit | 20.9 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Total Renal Care Of North Carolina Llc lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 742 |
Mortality Rate in facility | 18.5 (As Expected) |
Mortality Rate: Upper Confidence Limit | 22.7 |
Mortality Rate: Lower Confidence Limit | 14.9 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago
Total Renal Care Of North Carolina Llc Location: 14 Office Park Drive, Jacksonville, North Carolina, 28546 Phone: (910) 353-6888 |
Total Renal Care Of North Carolina, Llc Location: 111 Yopp Road, Jacksonville, North Carolina, 28540 Phone: (910) 989-0157 |
News Archive
New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.
A clinically relevant "liquid biopsy" test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer, according to new research published by a multi-institutional team of researchers with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard.
People at high risk for knee osteoarthritis may be nervous and reluctant to participate in strenuous physical activities such as jogging, cycling, singles tennis and skiing.
Ethicon Endo-Surgery, Inc., a Johnson & Johnson company, announced today that it has reached an agreement with Hologic, Inc., and Hologic subsidiary Suros Surgical Systems, Inc., settling litigation in Ohio and dismissing pending cases in Delaware. The disputes involved patents relating to the Ethicon Endo-Surgery MAMMOTOME® Breast Biopsy System, and the Hologic ATEC and EVIVA biopsy devices. Under the terms of the agreement, Ethicon Endo-Surgery will receive $12.5 million from Hologic.
› Verified 4 days ago